Dive Deeper into iProgen's Innovations
Team of Specialists
Ken Lee
Ken is a biotech entrepreneur with 25 years of experience in the field. Ken’s journey has seen him navigate through target discovery at the BC Cancer Research Center, preclinical research at Inimex Pharmaceuticals, clinical research management at BC Clinical Research, and business development roles at Helios & iProgen. He held a certification from RAPS in US Regulatory Affairs and was designated as a Clinical Research Professional by the Society of Clinical Research. Ken holds B.Sc. from UBC and MBA from the Richard Ivey School of Business.
Nigel McNabb
Nigel has 18 years of experience in corporate and business development across the public and private sectors including Health Canada, Deloitte, and Royal Bank of Canada. As a seasoned business development expert, Nigel has worked across a variety of roles, including as a Business Transformation Consultant, Business Architect, and Project Manager. His key areas of expertise include new business strategy, design and implementation all supported though performance management. Nigel holds a B.Sc. in Biology from the University of British Columbia and an MBA from the Richard Ivey School of Business.
Leo Lin
Leo brings over two decades of expertise in protein engineering and protein delivery technology, the founding scientist at iProgen has contributed immensely to our patent portfolio as a co-inventor; Leo spearheads all technological innovation at iProgen; completed post-doctoral work at Natalie Strynadka’s lab at UBC. Leo immigrated to Canada from Taiwan in his childhood and graduated with Ph.D., from McGill University with the Governor General’s Gold Medal.
Hans E. Huber
Retired distinguished scientist from Merck, spent almost two decades studying biologics and biologics drug delivery technology; currently an Associate Director of the Center for Targeted Therapeutics and Translational Nanomedicine at University of Pennsylvania. Hans received his Ph.D. from ETH and completed post-doc at Harvard.
MICHAEL GALLO
Michael is founder CEO of Innovative Targeting Solutions Inc. He was formerly the Vice President of Research at Abgenix Inc. and subsequently Amgen British Columbia, Michael oversaw numerous antibody discovery collaborations involving over 100 different targets with collaborators including AstraZeneca, Pfizer, Abbot, Curagen, Milleneum, and Dendreon.
Paula Lario
Over 20 years experience in engineering antibody; former Group lead at Zymeworks for developing its bispecific platforms; co-inventor of 20+ antibody engineering patents at both Zymeworks and iProgen; received Ph.D. is from McGill University and completed Post Doc at UBC
John Lambert
Over 30 years experience in ADC development, led preclinical and clinical development of a variety ADC programs at ImmunoGen including T-DM1; held various position including Chief Scientific Officer, Executive Vice President, Distinguished Research Fellow at Immunogen
Mike Sun
Over 20 years experience in ADC development, intimately familiar with GMP manufacturing of ADC for clinical development, held various role ranging from VP of Manufacturing at Silverback Therapeutics to Sr. Director of Clinical Manufacturing at Seattle Genetics
Ken is a biotech entrepreneur with 25 years of experience in the field. Ken’s journey has seen him navigate through target discovery at the BC Cancer Research Center, preclinical research at Inimex Pharmaceuticals, clinical research management at BC Clinical Research, and business development roles at Helios & iProgen. He held a certification from RAPS in US Regulatory Affairs and was designated as a Clinical Research Professional by the Society of Clinical Research. Ken holds B.Sc. from UBC and MBA from the Richard Ivey School of Business.
Leo brings over two decades of expertise in protein engineering and protein delivery technology, the founding scientist at iProgen has contributed immensely to our patent portfolio as a co-inventor; Leo spearheads all technological innovation at iProgen; completed post-doctoral work at Natalie Strynadka’s lab at UBC. Leo immigrated to Canada from Taiwan in his childhood and graduated with Ph.D., from McGill University with the Governor General’s Gold Medal.
Mr. Wood has over 30 years of experience in management of both early and late stage companies in North America and the U.K. and has over 18 years of experience in the biopharmaceutical industry, where he has overseen several M&A transactions and numerous financings. Prior to joining ESSA, Mr. Wood was Head of Finance, Secretary and Treasurer at Celator Pharmaceuticals Inc., now a subsidiary of Jazz Pharmaceuticals. He received a B.Sc. in Biology from Queen’s University, an M.B.A. from University of Western Ontario and holds a CPA, CMA accounting designation.
Ranjani is a seasoned biotechnology professional with more than 16 years of industry experience in research and operational management. Her portfolio includes, but not limited to, leading internal research projects and external collaborations, patent contributions and managing and mentoring staff. Her scientific expertise includes cell line development and recombinant protein production (cGMP) and characterization, antibody and ADC assay development.
Nigel has 18 years of experience in corporate and business development across the public and private sectors including Health Canada, Deloitte, and Royal Bank of Canada. As a seasoned business development expert, Nigel has worked across a variety of roles, including as a Business Transformation Consultant, Business Architect, and Project Manager. His key areas of expertise include new business strategy, design and implementation all supported though performance management. Nigel holds a B.Sc. in Biology from the University of British Columbia and an MBA from the Richard Ivey School of Business.
Michael is a Cambridge University educated corporate lawyer, entrepreneur, investor and philanthropist. Previously, he was civil litigator at McCarthy Tetrault and Robertson, Peck, Thompson, Casilio, Vancouver. Formerly, he was also Advisor to the House of Commons Standing Committee on Transport, Ottawa.
Hans is a retired distinguished scientist from Merck; he spent almost two decades studying biologics and biologics drug delivery technology; currently he is an Associate Director of the Center for Targeted Therapeutics and Translational Nanomedicine at University of Pennsylvania. Hans received his Ph.D. from ETH and completed post-doc at Harvard.
Michael is founder CEO of Innovative Targeting Solutions Inc. He was formerly the Vice President of Research at Abgenix Inc. and subsequently Amgen British Columbia, Michael oversaw numerous antibody discovery collaborations involving over 100 different targets with collaborators including AstraZeneca, Pfizer, Abbot, Curagen, Milleneum, and Dendreon.
Paula brings over 20 years experience in engineering antibody. She was the former Group lead at Zymeworks for developing its bispecific platforms. She is also co-inventor of 20+ antibody engineering patents at both Zymeworks and iProgen. Paula received Ph.D. is from McGill University and completed Post Doc at UBC.
John brings over 30 years experience in ADC development. He led preclinical and clinical development of a variety ADC programs at ImmunoGen including T-DM1 (Kadcyla). He held various position including Chief Scientific Officer, Executive Vice President, Distinguished Research Fellow at Immunogen.
Mike brings over 20 years experience in ADC development, and is intimately familiar with GMP manufacturing of ADC for clinical development. He held various role ranging from VP of Manufacturing at Silverback Therapeutics to Sr. Director of Clinical Manufacturing at Seattle Genetics.
Jennifer is a biotechnology-focused PhD scientist with 25+ years experience in working for global venture capital firms, big Pharma, and independent biotechnology companies. She was formerly Canada lead at Johnson & Johnson Innovation and Venture Partner at Nomura Phase4 Ventures.